Tranquilizers or anti-depressants for chronic schizophrenics: a long term study

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Chronic schizophrenia presents significant treatment challenges.
• Long-term hospitalization is common in severe schizophrenia cases.
• Evaluating antipsychotic efficacy and adjunct therapies is crucial.

Purpose of the Study:

• To compare the efficacy of four different tranquilizers in chronic schizophrenic patients.
• To investigate the added therapeutic benefit of amitriptyline when combined with tranquilizers.

Main Methods:

• A 16-week, double-blind, placebo-controlled trial involving 66 chronic schizophrenic patients.
• Patients received a 4-week placebo period, followed by 16 weeks of high-dose tranquilizer treatment.
• Amitriptyline was added for an additional 16 weeks to assess its adjunctive effect.

Main Results:

• Patients significantly worsened on placebo.
• All four tranquilizers demonstrated significant symptom reduction compared to placebo.
• Maximum therapeutic improvement was achieved within 16 weeks of tranquilizer administration.
• No significant differences in efficacy were found among the four tranquilizers.
• Adding amitriptyline did not provide additional therapeutic benefits.

Conclusions:

• High-dose tranquilizers are effective in reducing symptoms of chronic schizophrenia.
• Treatment duration beyond 16 weeks with tranquilizers does not appear to yield further significant improvement.
• Amitriptyline is not beneficial as an adjunct therapy in this patient population.